Our top pick for
Jaguar Health, Inc is a biotechnology business based in the US. Jaguar Health shares (JAGX) are listed on the NASDAQ and all prices are listed in US Dollars. Jaguar Health employs 29 staff and has a trailing 12-month revenue of around USD$6.5 million.
|52-week range||USD$0.284 - USD$0.96|
|50-day moving average||USD$0.3362|
|200-day moving average||USD$0.4886|
|Wall St. target price||USD$5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-79.453|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Jaguar Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jaguar Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Jaguar Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Jaguar Health shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$6.5 million|
|Gross profit TTM||USD$-3,782,372|
|Return on assets TTM||-38.14%|
|Return on equity TTM||-310.33%|
|Market capitalisation||USD$17.2 million|
TTM: trailing 12 months
There are currently 380,248 Jaguar Health shares held short by investors – that's known as Jaguar Health's "short interest". This figure is 68.1% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Jaguar Health shares can be evaluated.
Jaguar Health's "short interest ratio" (SIR) is the quantity of Jaguar Health shares currently shorted divided by the average quantity of Jaguar Health shares traded daily (recently around 5.4 million). Jaguar Health's SIR currently stands at 0.07. In other words for every 100,000 Jaguar Health shares traded daily on the market, roughly 70 shares are currently held short.
However Jaguar Health's short interest can also be evaluated against the total number of Jaguar Health shares, or, against the total number of tradable Jaguar Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jaguar Health's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Jaguar Health shares in existence, roughly 10 shares are currently held short) or 0.0078% of the tradable shares (for every 100,000 tradable Jaguar Health shares, roughly 8 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Jaguar Health.
Find out more about how you can short Jaguar Health stock.
We're not expecting Jaguar Health to pay a dividend over the next 12 months.
Jaguar Health's shares were split on a 1:70 basis on 7 June 2019. So if you had owned 70 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Jaguar Health shares – just the quantity. However, indirectly, the new 6900% higher share price could have impacted the market appetite for Jaguar Health shares which in turn could have impacted Jaguar Health's share price.
Over the last 12 months, Jaguar Health's shares have ranged in value from as little as $0.284 up to $0.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jaguar Health's is 0.9307. This would suggest that Jaguar Health's shares are less volatile than average (for this exchange).
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.